Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Raman Sankar

Neurodevelopmental Disabilities Los Angeles, CA Medical Doctor

NPI 1376629063 CMS profile 17411

10833 Le Conte Ave, 12-441 Mdcc, Los Angeles, CA 90095

Open in the dashboard

General payments

$1,100,083

1,406 records reported · program years 2019–2025

Research payments

$3,420

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,230 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Raman Sankar of Los Angeles, CA is reported in the CMS Open Payments database as having received $1,100,083 across 1,406 general payments and $3,420 in research payments paid to them. Separately, studies naming them as principal investigator received $11,230 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurodevelopmental Disabilities profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $280,418 319
2024 General $215,707 278
2024 Research $1,500 1
2023 General $206,321 317
2023 Research $420 1
2022 General $116,802 156
2021 General $81,695 104
2021 Research $1,500 1
2020 General $50,212 75
2019 General $148,927 157

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raman Sankar
  • Neurodevelopmental Disabilities median
  • Middle half of Neurodevelopmental Disabilities
  • National median

In program year 2025, general payments to Raman Sankar were reported at $280,418. Among 64 Neurodevelopmental Disabilities profiles paid that year, the median was $136 and the middle half received between $67 and $819.

Show as a table
Year Raman Sankar Neurodevelopmental Disabilities median Middle half National median
2019 $148,927 $138 $34–$757 $163
2020 $50,212 $63 $23–$471 $114
2021 $81,695 $158 $43–$1,017 $132
2022 $116,802 $225 $76–$1,106 $149
2023 $206,321 $228 $73–$994 $160
2024 $215,707 $167 $57–$1,310 $164
2025 $280,418 $136 $67–$819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $346,049 575 payments
  2. SK Life Science, Inc. $161,708 178 payments
  3. Neurelis, Inc. $154,988 151 payments
  4. Jazz Pharmaceuticals Inc. $109,912 143 payments
  5. Eisai Inc. $60,709 65 payments
  6. BioMarin Pharmaceutical Inc. $56,380 57 payments
  7. LivaNova USA, Inc. $50,833 56 payments
  8. Greenwich Biosciences, Inc. $40,573 49 payments
  9. Sunovion Pharmaceuticals Inc. $19,114 22 payments
  10. Vertex Pharmaceuticals Incorporated $17,735 12 payments
  11. Other $82,082 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $585,343 256 payments
  2. Travel and Lodging $187,703 583 payments
  3. Consulting Fee $155,178 57 payments
  4. Honoraria $136,861 56 payments
  5. Food and Beverage $34,944 450 payments
  6. Education $53 4 payments
Products named General payments · program years 2019–2025
  1. Fintepla $286,578 465 payments
  2. VALTOCO $154,988 151 payments
  3. XCOPRI $152,588 139 payments
  4. Epidiolex $150,154 188 payments
  5. Brineura $49,085 47 payments
  6. Fycompa $43,303 43 payments
  7. Briviact $29,357 46 payments
  8. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $25,526 15 payments
  9. Banzel $21,211 25 payments
  10. APTIOM $18,893 20 payments
  11. Other $98,418 151 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $3,000 2 payments
  2. UCB, Inc. $420 1 payment

Records

1,409 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurodevelopmental Disabilities in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record